Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 119.98% | 87.95% | 80.93% | 102.08% | 67.79% |
| Total Depreciation and Amortization | 13.57% | 17.30% | 16.81% | 15.67% | 10.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.13% | 186.88% | 258.92% | 250.08% | 455.31% |
| Change in Net Operating Assets | -4.92% | -42.19% | -40.80% | -76.27% | -795.66% |
| Cash from Operations | 166.27% | 142.54% | 153.50% | 107.96% | -2.94% |
| Capital Expenditure | -46.58% | -42.36% | -48.22% | -46.70% | -60.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 72.42% | 100.00% | 9.25% | 9.25% | -508.80% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.27% | -61.27% | -74.71% | -23.87% | -87.13% |
| Cash from Investing | 2.09% | -18.46% | -50.18% | -30.04% | -99.26% |
| Total Debt Issued | -17.76% | 2.53% | 2.53% | 31.99% | 320.01% |
| Total Debt Repaid | 62.70% | -10.32% | 122.66% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -943.31% | -- | -- | -233.33% | 40.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.94% | -15.00% | -15.07% | -15.02% | -15.11% |
| Other Financing Activities | -66.23% | -85.58% | -77.35% | -46.45% | -50.33% |
| Cash from Financing | -91.19% | -97.75% | 5.38% | -64.81% | 520.01% |
| Foreign Exchange rate Adjustments | -95.94% | 421.01% | -219.39% | -275.98% | 393.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 549.96% | -71.22% | 158.31% | -40.15% | 517.67% |